The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.
Mark Harrison
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
Sandy Beare
Research Funding - Roche
John A. Bridgewater
Research Funding - Roche
Ian Chau
Consultant or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck Serono; Novartis; Roche; Sanofi
Honoraria - Lilly; Sanofi ; Taiho Pharmaceutical
Research Funding - Merck; Novartis; Roche; Sanofi
Vicky Goh
No relevant relationships to disclose
Alec Mcdonald
No relevant relationships to disclose
Lucinda Melcher
No relevant relationships to disclose
Brendan J. Moran
No relevant relationships to disclose
Melanie Osborne
No relevant relationships to disclose
Philip Quirke
Research Funding - Roche
Harpreet Wasan
Other Remuneration - Roche
Wailup Wong
No relevant relationships to disclose
Robert Glynne-Jones
Consultant or Advisory Role - Roche
Research Funding - Roche